Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quintiles adds TMD to oncology portfolio

This article was originally published in Clinica

Executive Summary

Professional healthcare services company Quintiles Transnational has strengthened its oncology offering by purchasing Targeted Molecular Diagnostics (TMD), a laboratory specialising in tissue-based testing. The deal provides Quintiles (Research Triangle Park, North Carolina) with in-house pathology capabilities for tissue-based testing, which the firm describes as being “a critical component of the modern-day oncology drug development process”. According to Quintiles’ senior vice-president Tom Wollman, TMD also gives the company access to important biomarker expression analysis know-how. Westmont, Illinois-based TMD also supports clinical trials for both biotech and pharmaceutical companies around the world, and offers more than 100 biomarker assays. Financial terms of the acquisition were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel